Publication:
The American Society of Peritoneal Surface Malignancies Multi-Institution Evaluation of 1,051 Advanced Ovarian Cancer Patients Undergoing Cytoreductive Surgery and HIPEC: An Introduction of the Peritoneal Surface Disease Severity Score

dc.contributor.authorFoster, Jason M
dc.contributor.authorSleightholm, Richard
dc.contributor.authorSmith, Lynette
dc.contributor.authorCeelen, Wim
dc.contributor.authorDeraco, Marcello
dc.contributor.authorYildirim, Yusuf
dc.contributor.authorLevine, Edward
dc.contributor.authorMuñoz-Casares, Cristobal
dc.contributor.authorGlehen, Olivier
dc.contributor.authorPatel, Asish
dc.contributor.authorEsquivel, Jesus
dc.date.accessioned2023-01-25T10:22:55Z
dc.date.available2023-01-25T10:22:55Z
dc.date.issued2016-10-28
dc.description.abstractBackground: Standard treatment for ovarian epithelial cancer (OEC) consists of cytoreductive surgery (CRS) and a platinum-taxane chemotherapy combination. There is increasing interest in evaluating hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with stage IIIC/IV disease. The peritoneal surface disease severity score (PSDSS) was introduced as a basis to improve patient selection for this therapy in OEC. Methods: The charts of 1,051 patients with advanced OEC who underwent CRS/HIPEC were retrospectively evaluated using the following preoperatively obtained criteria: symptoms, peritoneal dissemination, and tumor histology. Overall survival was analyzed according to PSDSS as well as the timings and agents used during CRS/HIPEC. Results: Median survival for all 1,051 patients was 73.4 months. PSDSS information was available for 553 patients. Survival correlated negatively with PSDSS (P < 0.001). Furthermore, combining PSDSS scores into I/II and III/IV described two distinct patient populations with vastly different outcomes, 100 versus 55 months, respectively (P < 0.001). Multivariate analysis failed to describe any differences between timings of HIPEC or chemotherapy agents used. Conclusion: PSDSS was capable of identifying a better surviving patient population in advanced-stage OEC. While randomized trials to evaluate the benefit of HIPEC are needed, the PSDSS may be a useful tool for selecting and stratifying OEC patients in clinical trials.
dc.description.versionSi
dc.identifier.citationFoster JM, Sleightholm R, Smith L, Ceelen W, Deraco M, Yildirim Y, et al. The American Society of Peritoneal Surface Malignancies Multi-Institution evaluation of 1,051 advanced ovarian cancer patients undergoing cytoreductive surgery and HIPEC: An introduction of the peritoneal surface disease severity score. J Surg Oncol. 2016 Dec;114(7):779-784
dc.identifier.doi10.1002/jso.24603
dc.identifier.essn1096-9098
dc.identifier.pmid30295939
dc.identifier.unpaywallURLhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jso.24603
dc.identifier.urihttp://hdl.handle.net/10668/13041
dc.issue.number4
dc.journal.titleJournal of surgical oncology
dc.journal.titleabbreviationJ Surg Oncol
dc.language.isoen
dc.organizationHospital Universitario Reina Sofía
dc.page.number1
dc.provenanceRealizada la curación de contenido 21/07/2025
dc.publisherJohn Wiley and Sons
dc.pubmedtypeJournal Article
dc.relation.publisherversionhttps://doi.org/10.1002/jso.24406
dc.rights.accessRightsRestricted Access
dc.subjectPSDSS
dc.subjectOEC ovarian epithelial cancer
dc.subjectCRS
dc.subjectHIPEC
dc.subject.decsQuimioterapia intraperitoneal hipertérmica
dc.subject.decsProtocolos de quimioterapia combinada antineoplásica
dc.subject.decsSupervivencia sin enfermedad
dc.subject.decsTerapia neoadyuvante
dc.subject.decsHepatectomía
dc.subject.meshHyperthermic Intraperitoneal Chemotherapy
dc.subject.meshCarcinoma, Ovarian Epithelial
dc.subject.meshCytoreduction Surgical Procedures
dc.titleThe American Society of Peritoneal Surface Malignancies Multi-Institution Evaluation of 1,051 Advanced Ovarian Cancer Patients Undergoing Cytoreductive Surgery and HIPEC: An Introduction of the Peritoneal Surface Disease Severity Score
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number118
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
RISalud_Accesorestringido.pdf
Size:
93.39 KB
Format:
Adobe Portable Document Format